Merck Receives FDA Approval For Supplemental Biologics License Application For ENFLONSIA To Expand Indication To Prevention Of Respiratory Syncytial Virus Lower Respiratory Tract Disease In Children Under Two Years Of Age At Increased Risk For Severe RSV Disease; PDUFA Date Set For March 22, 2027

뉴스 본문을 불러오고 있어요.

Merck Receives FDA Approval For Supplemental Biologics License Application For ENFLONSIA To Expand Indication To Prevention Of Respiratory Syncytial Virus Lower Respiratory Tract Disease In Children Under Two Years Of Age At Increased Risk For Severe RSV Disease; PDUFA Date Set For March 22, 2027 | 웨이프 WAPE

Merck Receives FDA Approval For Supplemental Biologics License Application For ENFLONSIA To Expand Indication To Prevention Of Respiratory Syncytial Virus Lower Respiratory Tract Disease In Children Under Two Years Of Age At Increased Risk For Severe RSV Disease; PDUFA Date Set For March 22, 2027

기사 요약

관련 종목

댓글 —